TY - JOUR
T1 - Role of parity and human papillomavirus in cervical cancer
T2 - The IARC multicentric case-control study
AU - Muñoz, Nubia
AU - Franceschi, Silvia
AU - Bosetti, Cristina
AU - Moreno, Victor
AU - Herrero, Rolando
AU - Smith, Jennifer S.
AU - Shah, Keerti V.
AU - Meijer, Chris J.L.M.
AU - Bosch, F. Xavier
N1 - Funding Information:
This research was funded by WHO grant 98101; European Community grant CI 1–0371–F(CD); the Fondo de Investigaciones Sanitarias (FIS), Spain, grants 86/753, 87/1513, 88/2049, 90/0901, and 95/0655; Preventiefonds, Netherlands, grant 28–1502·1; Programa Interministerial de Investigación y Desarrollo, Spain, grant SAF 96/0323; and the Conselho Nacional de Desenvolvimiento Cientifico e Tecnologico, Brazil, grant JEN-204453/88·7.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2002/3/30
Y1 - 2002/3/30
N2 - Background: High parity has long been suspected of being associated with an increased risk of cervical cancer, but previous analyses of this association have not taken the strong effect of human papillomavirus (HPV) into account. To assess the role of reproductive factors in the progression from HPV infection to cancer, we did a pooled analysis including only HPV-positive women. Methods: We pooled data from eight case-control studies on invasive cervical carcinoma (ICC) and two on in-situ carcinoma (ISC) from four continents. 1465 patients with squamous-cell ICCs, 211 with ISCs, 124 with adenocarcinomas or adenosquamous ICCs, and 255 control women, all positive for HPV DNA by PCR-based assays, were analysed. We calculated pooled odds ratios by means of unconditional multiple logistic regression models, and adjusted them for sexual and non-sexual confounding factors. The 95% CI were estimated by treating the odds ratio as floating absolute risk. Findings: We found a direct association between the number of full-term pregnancies and squamous-cell cancer risk: the odds ratio for seven full-term pregnancies or more was 3.8 (95% CI 2.7-5.5) compared with nulliparous women, and 2.3 (1.6-3.2) compared with women who had one or two full-term pregnancies. There was no significant association between risk of adenocarcinoma or adenosquamous carcinoma and number of full-term pregnancies. Interpretation: High parity increases the risk of squamous-cell carcinoma of the cervix among HPV-positive women. A general decline in parity might therefore partly explain the reduction in cervical cancer recently seen in most countries.
AB - Background: High parity has long been suspected of being associated with an increased risk of cervical cancer, but previous analyses of this association have not taken the strong effect of human papillomavirus (HPV) into account. To assess the role of reproductive factors in the progression from HPV infection to cancer, we did a pooled analysis including only HPV-positive women. Methods: We pooled data from eight case-control studies on invasive cervical carcinoma (ICC) and two on in-situ carcinoma (ISC) from four continents. 1465 patients with squamous-cell ICCs, 211 with ISCs, 124 with adenocarcinomas or adenosquamous ICCs, and 255 control women, all positive for HPV DNA by PCR-based assays, were analysed. We calculated pooled odds ratios by means of unconditional multiple logistic regression models, and adjusted them for sexual and non-sexual confounding factors. The 95% CI were estimated by treating the odds ratio as floating absolute risk. Findings: We found a direct association between the number of full-term pregnancies and squamous-cell cancer risk: the odds ratio for seven full-term pregnancies or more was 3.8 (95% CI 2.7-5.5) compared with nulliparous women, and 2.3 (1.6-3.2) compared with women who had one or two full-term pregnancies. There was no significant association between risk of adenocarcinoma or adenosquamous carcinoma and number of full-term pregnancies. Interpretation: High parity increases the risk of squamous-cell carcinoma of the cervix among HPV-positive women. A general decline in parity might therefore partly explain the reduction in cervical cancer recently seen in most countries.
UR - http://www.scopus.com/inward/record.url?scp=0037197040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037197040&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(02)08151-5
DO - 10.1016/S0140-6736(02)08151-5
M3 - Article
C2 - 11943256
AN - SCOPUS:0037197040
SN - 0140-6736
VL - 359
SP - 1093
EP - 1101
JO - Lancet
JF - Lancet
IS - 9312
ER -